

Pharmacogenomics Market Research Explores Growth Within A \$15.97 Billion Opportunity

*The Business Research Company's
Pharmacogenomics Market Research
Explores Growth Within A \$15.97 Billion
Opportunity*

LONDON, GREATER LONDON, UNITED
KINGDOM, August 24, 2026

/EINPresswire.com/ -- "The

[pharmacogenomics market](#) is gaining

significant attention as advances in genetic research and personalized medicine reshape treatment approaches. With growing investments and technological progress, this field is poised for remarkable expansion in the coming years. Let's explore the market size, growth drivers, key regional insights, and emerging trends shaping the pharmacogenomics landscape.

“

Expected to grow to \$15.98 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%”

*The Business Research
Company*

[Pharmacogenomics Market Size](#) and Growth Outlook

The pharmacogenomics market has experienced rapid expansion recently, increasing from \$9.84 billion in 2025 to an anticipated \$10.85 billion in 2026. This growth corresponds to a compound annual growth rate (CAGR) of 10.3%. The rise in market size during this period is primarily fueled by enhanced genomic research, broader development of targeted therapies, increasing prevalence

of chronic diseases, advancements in sequencing technologies, and greater access to genetic testing services.

Download a free sample of the [pharmacogenomics market report](#):

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Aug_PR

Looking ahead, the pharmacogenomics market is projected to grow further, reaching \$15.98 billion by 2030 at a CAGR of 10.2%. The expected growth during this forecast period is driven by heightened investments in precision medicine initiatives, a surge in the use of AI-based genomic analysis, expansion of pharmacogenomics applications in oncology and cardiology, increased focus on personalized drug development, and ongoing improvements in bioinformatics

The Business
Research Company

The Business Research Company



platforms. Key trends include wider adoption of personalized medicine, integration of genetic testing in drug selection processes, expanded use of pharmacogenomic data in clinical workflows, growth of companion diagnostics, and a stronger emphasis on precision therapeutics.

Understanding Pharmacogenomics and Its Applications

Pharmacogenomics studies how individuals' genetic profiles influence their responses to medications. The ultimate goal is to guide healthcare providers in selecting the most effective drugs and doses tailored to each patient. This approach helps develop customized therapies for treating various conditions, such as cardiovascular diseases, Alzheimer's disease, cancer, and asthma. The term pharmacogenomics marker refers to the delivery of precise medical treatment suited to individuals or specific patient groups.

View the full pharmacogenomics market report:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Aug_PR

Rising Chronic Diseases as a Key Growth Driver for Pharmacogenomics

The growing prevalence of chronic diseases is a major factor driving the pharmacogenomics market forward. Chronic conditions typically persist over a long period, often throughout a person's lifetime. Factors such as increased global life expectancy and widespread lifestyle risk behaviors—including sedentary habits, poor nutrition, and tobacco use—contribute to this rise. Pharmacogenomics provides a personalized treatment framework that accounts for genetic variations influencing drug efficacy and safety in chronic disease management. For example, the International Diabetes Federation reported that approximately 589 million adults aged 20 to 79 were living with diabetes in 2024, and this number is projected to climb to 853 million by 2050, with the majority living in low- and middle-income countries. This increasing burden of chronic diseases strongly supports the expansion of the pharmacogenomics market.

Regional Perspectives on the Pharmacogenomics Market

In 2025, North America held the largest share of the pharmacogenomics market, benefiting from advanced healthcare infrastructure and extensive research activities. Meanwhile, the Asia-Pacific region is expected to emerge as the fastest-growing market during the forecast period, driven by increasing healthcare investments and rising awareness of personalized medicine. The market report covers additional regions such as South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a thorough view of global market dynamics.

Key enhancements in our 2026 market reports include:

- Market attractiveness scoring and analysis
- Total addressable market (TAM) analysis
- Company scoring matrix graphics and tables
- Excel-based forecasting dashboards

- Market hotspots infographics
- Key technologies and future trend analysis
- Updated graphics and tables

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: marketing@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

- LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/936555750>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.